Market News / Story
FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III…
BusinessWire ·
BusinessWire reports: Genentech, a member of the Roche Group ( , ROP; ), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumor characterized by high mutation rates. This approval marks the twelfth indication for Tecentriq…
Related stories
French bonds are suffering through its worst decade since 1803 - and investors are bracing for more painRead story summary
France's massive budget deficit pushed borrowing costs up to multidecade highs - and it turns out the moves were even more historic than that. The French budget deficit is set to reach 5.4% of gross domestic product this year, significantly higher than any other member of the European Union and above the bloc's 3% limit. The country has not managed to run a ...
VIEW SOURCE
Higher bond yields are raising the bar for stocks: Stan WongRead story summary
For much of this year, “higher for longer” was a warning. Now it is a market reality. With the U.S. 10-year Treasury yield above 5.25 per cent and touching a two-decade high, borrowing costs are becoming harder for markets to ignore. Bonds also compete more directly with equities for investor capital. The implications for equity valuations are significant. ...
VIEW SOURCE
ECB's Dolenc: Persistently Elevated Inflation Supports The Case For Moving Policy Rates Towards A More Restrictive TerritoryRead story summary
ECBs Dolenc: Risks Skewed To The Upside On Oil, Gas, Food, Strong Growth - Persistently Elevated Inflation Supports The Case For Moving Policy Rates Towards A More Restrictive Territory - More Stable Core Provides Some Reassurance That Broader Price Pressures Contained Ecb's Dolenc: Inflation Risks Skewed To The Upside On Oil, Gas, Food, Strong Growth ; More Stable Core Provides Some Reassurance That Broader Price Pressures Contained #oott
VIEW SOURCE